What is Taiwan Advance Bio-Pharmaceutical Days Payable?
Taiwan Advance Bio-PharmaceuticalROCO:4186 52 Days Payable is 10.40 as of Dec. 2025, which is 33% below its 10-year median of 15.56. GuruFocus rates ROCO:4186 with a GF Score™ of 52/100 and a GF Value™ of NT$17.90 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 701 Biotechnology companies, Taiwan Advance Bio-Pharmaceutical ranks worse than 96.43% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical Days Payable Chart
ROCO:4186 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advance Bio-Pharmaceutical Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's Days Payable distribution charts can be found below:
* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's Days Payable falls into.
Taiwan Advance Bio-Pharmaceutical Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a Days Payable of 10.40 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. This is 33% below median its historical median of 15.56. Over the past decade, Taiwan Advance Bio-Pharmaceutical's Days Payable has ranged from 9.30 to 24.67. According to the industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #676 out of 701 companies in the Biotechnology industry, placing it in the top 96.4%.
Is Taiwan Advance Bio-Pharmaceutical's Days Payable too high?
Taiwan Advance Bio-Pharmaceutical's current Days Payable of 10.40 is 33% below median its 10-year median of 15.56. Over the past 10 years, this metric has ranged from a low of 9.30 to a high of 24.67. The Biotechnology industry median Days Payable is 112.84. Taiwan Advance Bio-Pharmaceutical's value of 10.40 is 90.8% below this industry median. Based on the distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #676 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #676 out of 701 companies for Days Payable. This places Taiwan Advance Bio-Pharmaceutical in the lower half of its industry. The industry median Days Payable is 112.84. Taiwan Advance Bio-Pharmaceutical's value of 10.40 is 90.8% below this benchmark. Historically, Taiwan Advance Bio-Pharmaceutical's own Days Payable has ranged from 9.30 to 24.67 over the past decade. While the company's 10-year median is 15.56 vs. the industry median of 112.84, Taiwan Advance Bio-Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Advance Bio-Pharmaceutical's current Days Payable of 10.40 is 90.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advance Bio-Pharmaceutical's current Days Payable is 10.40, which is 33% below median its own 10-year median of 15.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.90, compared to a current price of NT$10.05 — trading 43.9% below its estimated fair value. The current Days Payable is 10.40, which is 33% below median its 10-year median of 15.56 and 90.8% below the Biotechnology industry median of 112.84. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current Days Payable is 10.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued.
The current stock price of NT$10.05 is trading 43.9% below its estimated GF Value™ of NT$17.90.
GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:4186:
Days Payable: 10.40 (33% below median its 10-year median of 15.56)
GF Value™: NT$17.90 vs. price of NT$10.05 (43.9% below fair value)
Industry Position: 90.8% below the Biotechnology median (#676 of 701)
No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advance Bio-Pharmaceutical Business Description
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
52GF Score
Get the complete analysis for ROCO:4186
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4186 has been successfully added to your 
